Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3…